IL-18 Names Picking Up Interest in Cancer
Insights - One of the names we wrote about back in mid-December as a trade due to its ample cash position and negative enterprise value was Mural … Continue Reading
PremiumMust Read
2024 Trends to Watch as Biotech Makes Comeback
Biotech has roared back and seen a strong start to the new year. Since November, in less than 3 months,...
Read NowBig Pharma’s M&A Strategy Is Likely to Stay the Same in 2024
Bristol Myers Squibb announced the acquisition of Karuna (KRTX) for $14B to add a first-in-class schizophrenia drug and neuroscience pipeline....
Read NowLatest Posts
GLP & MASH Names Heating Up With More Data Announcements
Insights - In a prior note, we covered the impact that GLP-1 drug class would have on related markets. On this note, we’ll focus on NASH (now … Continue Reading
Read now
Transcript of KOL Call: Urologist Talks Bladder Cancer and Lasting Side Effects
Insights - Participants PropThink Dr. Michael Chancellor, KOL Jonathan Kaufman, Lipella CEO PropThink Good afternoon everyone, welcome to PropThink’s Digital Conference. My name is Deniel Mero, Editor … Continue Reading
Read nowModular Medical Submits 510(k) for Insulin Patch Pump
Insights - Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately six months to approve devices … Continue Reading
Premium
2024 Trends to Watch as Biotech Makes Comeback
Insights - Biotech has roared back and seen a strong start to the new year. Since November, in less than 3 months, the XBI is up 32%. … Continue Reading
Read now
Big Pharma’s M&A Strategy Is Likely to Stay the Same in 2024
Insights - Bristol Myers Squibb announced the acquisition of Karuna (KRTX) for $14B to add a first-in-class schizophrenia drug and neuroscience pipeline. You can read more about … Continue Reading
Read now
Awaited Catalysts in Obesity & Radiopharmaceutical Markets Miss Expectations
Insights - Yesterday, both obesity and radiopharmaceuticals had year end catalysts that unfortunately did not meet investor expectations. Structure (GPCR) Weight Loss UpdateGPCR traded down 42% on … Continue Reading
Read now